Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies

about

Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies

Item

http://www.wikidata.org/entity/Q58739975

description

wetenschappelijk artikel

@nl

наукова стаття, опублікована у вересні 2018

@uk

name

Resistance to FLT3 inhibitors ...... s and resensitizing strategies

@en

Resistance to FLT3 inhibitors ...... s and resensitizing strategies

@nl

type

Item

label

Resistance to FLT3 inhibitors ...... s and resensitizing strategies

@en

Resistance to FLT3 inhibitors ...... s and resensitizing strategies

@nl

prefLabel

Resistance to FLT3 inhibitors ...... s and resensitizing strategies

@en

Resistance to FLT3 inhibitors ...... s and resensitizing strategies

@nl

P1476

Resistance to FLT3 inhibitors ...... s and resensitizing strategies

@en

P2093

Jianbiao Zhou

http://www.w3.org/2001/XMLSchema#string

Wee-Joo Chng

http://www.w3.org/2001/XMLSchema#string

P2860

Downstream molecular pathways of FLT3 in the pathogenesis of acute myeloid leukemia: biology and therapeutic implications

FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L).

Aberrant splicing and drug resistance in AML

The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death

Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges

PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.

Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the Unite

P304

90-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.5306/WJCO.V9.I5.90

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-09-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30254964

http://www.w3.org/2001/XMLSchema#string

P921

leukemia

P932

6153124

http://www.w3.org/2001/XMLSchema#string